21 results
424B3
BIAF
bioAffinity Technologies, Inc.
23 Sep 24
Prospectus supplement
4:00pm
to commercialize our diagnostic tests or therapeutic products on our own include:
our inability to recruit, train, and retain adequate numbers
424B5
BIAF
bioAffinity Technologies, Inc.
5 Aug 24
Prospectus supplement for primary offering
9:00am
include:
our inability to recruit, train, and retain adequate numbers of effective sales, technical support, and marketing personnel;
the inability
424B3
BIAF
bioAffinity Technologies, Inc.
16 Apr 24
Prospectus supplement
7:19pm
functions.
Factors that may inhibit our efforts to commercialize our diagnostic tests or therapeutic products on our own include:
our inability to recruit
POS AM
npmvwfr7
1 Apr 24
Prospectus update (post-effective amendment)
8:06pm
424B5
fqu33x4uwpa onj3
8 Mar 24
Prospectus supplement for primary offering
12:18pm
424B5
r7tmstxy0wk
7 Mar 24
Prospectus supplement for primary offering
9:57pm
424B5
sdnm7qwywy3d77 43
28 Nov 23
Prospectus supplement for primary offering
4:00pm
S-3
qo4u9b3fi7e zwc
16 Nov 23
Shelf registration
5:23pm
DRS
hf6t9j
14 Aug 23
Draft registration statement
12:00am
8-K
EX-99.1
osy exef3jsojw
31 Mar 23
Results of Operations and Financial Condition
7:12pm
424B4
h830upi2u9
2 Sep 22
Prospectus supplement with pricing info
3:25pm